In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Kyverna Therapeutics Inc. (NASDAQ: KYTX) closed at $4.89 down -6.50% from its previous closing price of $5.23. In other words, the price has decreased by -$6.50 from its previous closing price. On the day, 0.61 million shares were traded. KYTX stock price reached its highest trading level at $5.275 during the session, while it also had its lowest trading level at $4.79.
Ratios:
For a deeper understanding of Kyverna Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.86 and its Current Ratio is at 14.86. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 03, 2024, initiated with a Neutral rating and assigned the stock a target price of $8.
On March 04, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.
On March 04, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.Morgan Stanley initiated its Overweight rating on March 04, 2024, with a $40 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 12 ’24 when Vida Ventures, LLC bought 253,136 shares for $22.00 per share. The transaction valued at 5,568,992 led to the insider holds 252,553 shares of the business.
Bain Capital Life Sciences Inv bought 450,000 shares of KYTX for $9,900,000 on Feb 12 ’24. The 10% Owner now owns 3,163,868 shares after completing the transaction at $22.00 per share. On Feb 12 ’24, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 910,000 shares for $22.00 each. As a result, the insider paid 20,020,000 and bolstered with 4,126,119 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 225889136 and an Enterprise Value of -125249896.
Stock Price History:
Over the past 52 weeks, KYTX has reached a high of $35.06, while it has fallen to a 52-week low of $5.15. The 50-Day Moving Average of the stock is -34.32%, while the 200-Day Moving Average is calculated to be -67.57%.
Shares Statistics:
For the past three months, KYTX has traded an average of 473.36K shares per day and 532020 over the past ten days. A total of 43.12M shares are outstanding, with a floating share count of 17.68M. Insiders hold about 59.03% of the company’s shares, while institutions hold 37.38% stake in the company. Shares short for KYTX as of 1726185600 were 2381602 with a Short Ratio of 5.03, compared to 1723680000 on 2933670. Therefore, it implies a Short% of Shares Outstanding of 2381602 and a Short% of Float of 7.180000000000001.
